Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SME Pharma Log on to Off-Patent Mart (India)

This article was originally published in PharmAsia News

Executive Summary

In the next few years, a number of small to medium size Indian pharmaceutical manufacturers will be jumping on the high-quality manufacturing bandwagon. Joining such giants as Ranbaxy and Dr Reddy's, companies setting up these facilities have their sights set on penetrating the stiffly regulated U.S. and European drug markets. In the next few years, a number of blockbuster drugs will be going off-patent, paving the way for Indian generics producers to swoop into the market. Currently, there are between 40 and 50 new facilities expected to be commissioned in the next year or so. These new plants will join more than 100 plants already certified by the U.S. FDA. Already 20 percent to 30 percent of active pharmaceutical ingredients for U.S. drugs are produced in India. That figure is expected to grow by 10 percent to 15 percent in the next several years. Companies with new facilities in the works include Bal Pharma, Paras Pharma, Venus Remedies, Syrya Organics and Chemicals, UnijulesLife Sciences, Centaur Pharma, Flamingo Pharma, Kemwell, Coral Labs, Ipca Labs, Poly Medicure, Twilight Likaka, RPG Life Sciences, Ankur Drugs, and Alpa Labs. (Click here for more
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC065698

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel